Mian, A. A., Haberbosch, I., Khamaisie, H., Agbarya, A., Pietsch, L., Eshel, E., . . . Mahajna, J. (2021). Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K). Ann Hematol.

Mian, Afsar Ali, et al. "Crizotinib Acts As ABL1 Inhibitor Combining ATP-binding With Allosteric Inhibition and Is Active against Native BCR-ABL1 and Its Resistance and Compound Mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)." Ann Hematol 2021.

Mian, Afsar Ali, et al. "Crizotinib Acts As ABL1 Inhibitor Combining ATP-binding With Allosteric Inhibition and Is Active against Native BCR-ABL1 and Its Resistance and Compound Mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)." Ann Hematol 2021.